Cantor Fitzgerald Expects Weaker Earnings for GH Research

GH Research PLC (NASDAQ:GHRS - Free Report) - Cantor Fitzgerald dropped their FY2025 EPS estimates for shares of GH Research in a report released on Monday, May 12th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will earn ($0.84) per share for the year, down from their previous forecast of ($0.79). Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for GH Research's current full-year earnings is ($0.80) per share.

GH Research (NASDAQ:GHRS - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.42.

Other equities research analysts also recently issued research reports about the company. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of GH Research in a research report on Friday, May 9th. Stifel Nicolaus lifted their price objective on shares of GH Research from $18.00 to $32.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. Guggenheim dropped their price target on GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Finally, Royal Bank of Canada assumed coverage on shares of GH Research in a research note on Friday, March 7th. They issued an "outperform" rating and a $31.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $30.43.

GH Research Trading Down 0.2%

Shares of NASDAQ GHRS traded down $0.03 during trading hours on Wednesday, reaching $10.96. The stock had a trading volume of 33,034 shares, compared to its average volume of 176,579. GH Research has a 52-week low of $6.00 and a 52-week high of $20.50. The business's fifty day moving average price is $10.28 and its two-hundred day moving average price is $9.95. The firm has a market cap of $569.97 million, a price-to-earnings ratio of -13.79 and a beta of 0.86.

Hedge Funds Weigh In On GH Research

Several institutional investors have recently modified their holdings of the business. Cormorant Asset Management LP lifted its position in shares of GH Research by 238.8% during the 1st quarter. Cormorant Asset Management LP now owns 2,009,482 shares of the company's stock worth $22,165,000 after buying an additional 1,416,439 shares during the last quarter. Jefferies Financial Group Inc. purchased a new stake in GH Research in the 1st quarter valued at approximately $8,272,000. Lynx1 Capital Management LP boosted its stake in shares of GH Research by 15.8% in the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company's stock valued at $34,013,000 after buying an additional 663,100 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in shares of GH Research in the 1st quarter valued at about $5,018,000. Finally, RA Capital Management L.P. lifted its stake in shares of GH Research by 3.9% in the first quarter. RA Capital Management L.P. now owns 6,944,648 shares of the company's stock valued at $76,599,000 after purchasing an additional 257,959 shares during the period. Institutional investors and hedge funds own 56.90% of the company's stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).